









Markets
/
Stocks
/
nasdaq-glpg
/

Galapagos NV

GLPG

28.930USD

-1.040-3.47%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

1.91BMarket Cap

6.98P/E TTM



Galapagos NV

28.930

-1.040-3.47%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Galapagos NV

Currency: USD Updated: 2026-03-27

Key Insights

Galapagos NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at 33.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Galapagos NV's Score

Industry at a Glance

Industry Ranking

98 / 391

Overall Ranking

213 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Galapagos NV Highlights

StrengthsRisks

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 326.60% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 944.91M.

Fairly Valued

The company’s latest PE is 6.98, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 15.28M shares, decreasing 30.79% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 803.00 shares of this stock.

Analyst Rating

Based on 3 analysts

Sell

Current Rating

33.000

Target Price

+10.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Galapagos NV is 8.45, ranking 36 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 765.29M, representing a year-over-year increase of 964.38%, while its net profit experienced a year-over-year increase of 2656.91%.

Score

Industry at a Glance

Previous score

8.45

Change



Financials

7.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.08

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.68

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Galapagos NV's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Galapagos NV is 8.15, ranking 60 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 6.98, which is 280.00% below the recent high of 26.51 and 380.49% above the recent low of -19.57.

Score

Industry at a Glance

Previous score

8.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Galapagos NV is 4.50, ranking 351 out of 391 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 32.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

4.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Sell

Current Rating

33.000

Target Price

+10.74%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Galapagos NV

GLPG

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Galapagos NV is 6.56, ranking 197 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 32.63 and the support level at 27.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.61

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.687

Sell

RSI(14)

30.332

Neutral

STOCH(KDJ)(9,3,3)

8.046

Oversold

ATR(14)

0.975

High Vlolatility

CCI(14)

-170.074

Sell

Williams %R

97.586

Oversold

TRIX(12,20)

-0.357

Sell

StochRSI(14)

0.062

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

30.248

Sell

MA10

31.390

Sell

MA20

32.177

Sell

MA50

33.263

Sell

MA100

32.575

Sell

MA200

32.197

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Galapagos NV is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 23.19%, representing a quarter-over-quarter increase of 0.66%. The largest institutional shareholder is Steven Cohen, holding a total of 486.21K shares, representing 0.74% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences Inc

16.71M

Tang Capital Management, LLC

4.29M

+3.42%

Madison Avenue Partners LP

2.20M

+16.98%

EcoR1 Capital, LLC

1.67M

+60.77%

Columbia Threadneedle Investments (US)

1.42M

+2490.14%

Prosight Capital

1.15M

-35.16%

Point72 Asset Management, L.P.

Star Investors

443.87K

+29.98%

Greenlight Capital, Inc.

Star Investors

482.75K

Segall Bryant & Hamill, LLC

487.20K

-2.77%

UBS Financial Services, Inc.

153.00K

-35.86%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Galapagos NV is 7.17, ranking 17 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.